Guangzhou and London – May 22, 2025 – Bio-Thera Solutions,Ltd (688177:SH), a commercial-stage biopharmaceutical company developing apipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC,along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announcedtha...
DetailsGUANGZHOU,China, October 24, 2023 -- Bio-Thera Solutions, Ltd (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of biosimilarsand innovative assets, announced that the National Health Surveillance Agency(“ANVISA”) published the approval of the certification of good m...
TOFIDENCE is Bio-Thera’s first productapproved by USFDA. TOFIDENCE is the first monoclonal antibodydrug researched, developed, and manufactured by a Chinese pharmaceuticalcompany to receive FDA approval in the United States TOFIDENCE is the first biosimilar toActemra approved by USFDA GUANGZHOU, C...
GUANGZHOU,China --(PR Newswire) -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceuticalcompany developing a pipeline of innovative and biosimilars, today announcedpositive Phase 1 clinical data for BAT8006 (Folate-Receptor-α-ADC) as part of apresentation of the clinical result...
